Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | KIT |
Variant | K558_V559del |
Impact List | deletion |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | KIT K558_V559del results in the deletion of two amino acids in the juxtamembrane domain (exon 11) of the Kit protein from amino acids 558 to 559 (PMID: 16226710). K558_V559del has not been characterized, however similar Kit exon 11 deletions are activating (PMID: 9438854, PMID: 15365079), and therefore, is predicted to lead to a gain of Kit protein function. |
Associated Drug Resistance | |
Category Variants Paths |
KIT mutant KIT act mut KIT exon 11 del KIT K558_V559del KIT mutant KIT exon11 KIT exon 11 del KIT K558_V559del |
Transcript | NM_000222.3 |
gDNA | chr4:g.54727440_54727445delAAGGTT |
cDNA | c.1672_1677delAAGGTT |
Protein | p.K558_V559delKV |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_017008180.1 | chr4:g.54727452_54727457delGAGATA | c.1672_1677delGAGATA | p.E558_I559delEI | RefSeq | GRCh38/hg38 |
XM_005265740 | chr4:g.54727437_54727442delTGGAAG | c.1672_1677delTGGAAG | p.W558_K559delWK | RefSeq | GRCh38/hg38 |
NM_001385286.1 | chr4:g.54727452_54727457delGAGATA | c.1672_1677delGAGATA | p.E558_I559delEI | RefSeq | GRCh38/hg38 |
XM_017008179 | chr4:g.54727449_54727454delGAGGAG | c.1672_1677delGAGGAG | p.E558_E559delEE | RefSeq | GRCh38/hg38 |
NM_001093772.2 | chr4:g.54727452_54727457delGAGATA | c.1672_1677delGAGATA | p.E558_I559delEI | RefSeq | GRCh38/hg38 |
NM_001385290.1 | chr4:g.54727437_54727442delTGGAAG | c.1672_1677delTGGAAG | p.W558_K559delWK | RefSeq | GRCh38/hg38 |
NM_001385285.1 | chr4:g.54727440_54727445delAAGGTT | c.1672_1677delAAGGTT | p.K558_V559delKV | RefSeq | GRCh38/hg38 |
NM_000222.3 | chr4:g.54727440_54727445delAAGGTT | c.1672_1677delAAGGTT | p.K558_V559delKV | RefSeq | GRCh38/hg38 |
XM_005265741.1 | chr4:g.54727437_54727442delTGGAAG | c.1672_1677delTGGAAG | p.W558_K559delWK | RefSeq | GRCh38/hg38 |
XM_017008179.1 | chr4:g.54727449_54727454delGAGGAG | c.1672_1677delGAGGAG | p.E558_E559delEE | RefSeq | GRCh38/hg38 |
NM_001385292.1 | chr4:g.54727449_54727454delGAGGAG | c.1672_1677delGAGGAG | p.E558_E559delEE | RefSeq | GRCh38/hg38 |
XM_017008178 | chr4:g.54727440_54727445delAAGGTT | c.1672_1677delAAGGTT | p.K558_V559delKV | RefSeq | GRCh38/hg38 |
NM_000222 | chr4:g.54727440_54727445delAAGGTT | c.1672_1677delAAGGTT | p.K558_V559delKV | RefSeq | GRCh38/hg38 |
XM_005265741 | chr4:g.54727437_54727442delTGGAAG | c.1672_1677delTGGAAG | p.W558_K559delWK | RefSeq | GRCh38/hg38 |
NM_001385288.1 | chr4:g.54727449_54727454delGAGGAG | c.1672_1677delGAGGAG | p.E558_E559delEE | RefSeq | GRCh38/hg38 |
NM_000222.2 | chr4:g.54727440_54727445delAAGGTT | c.1672_1677delAAGGTT | p.K558_V559delKV | RefSeq | GRCh38/hg38 |
XM_005265740.1 | chr4:g.54727437_54727442delTGGAAG | c.1672_1677delTGGAAG | p.W558_K559delWK | RefSeq | GRCh38/hg38 |
NM_001093772.1 | chr4:g.54727452_54727457delGAGATA | c.1672_1677delGAGATA | p.E558_I559delEI | RefSeq | GRCh38/hg38 |
XM_005265742 | chr4:g.54727449_54727454delGAGGAG | c.1672_1677delGAGGAG | p.E558_E559delEE | RefSeq | GRCh38/hg38 |
NM_001385284.1 | chr4:g.54727437_54727442delTGGAAG | c.1672_1677delTGGAAG | p.W558_K559delWK | RefSeq | GRCh38/hg38 |
XM_017008180 | chr4:g.54727452_54727457delGAGATA | c.1672_1677delGAGATA | p.E558_I559delEI | RefSeq | GRCh38/hg38 |
XM_005265742.3 | chr4:g.54727449_54727454delGAGGAG | c.1672_1677delGAGGAG | p.E558_E559delEE | RefSeq | GRCh38/hg38 |
XM_017008178.1 | chr4:g.54727440_54727445delAAGGTT | c.1672_1677delAAGGTT | p.K558_V559delKV | RefSeq | GRCh38/hg38 |
NM_001093772 | chr4:g.54727452_54727457delGAGATA | c.1672_1677delGAGATA | p.E558_I559delEI | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT K558_V559del | gastrointestinal stromal tumor | predicted - sensitive | Binimetinib + Imatinib | Case Reports/Case Series | Actionable | In a Phase II trial, Gleevec (imatinib) and Mektovi (binimetinib) combination treatment resulted in a 70% pathological response and 46% RECIST response in a patient with a rectal gastrointestinal stromal tumor harboring KIT K558_V559del (PMID: 35041493; NCT01991379). | 35041493 |